Lee's Pharmaceutical Holdings Limited functions as an investment holding company primarily focused on the development, manufacturing, and commercialization of pharmaceutical products within the People's Republic of China. The company's therapeutic scope is broad, addressing various medical conditions across diverse areas such as cardiovascular health, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. Its business operations are structured into two main segments: Proprietary and Generic Products, and Licensed-In Products. The Proprietary and Generic Products segment is responsible for producing and selling both its own internally developed medications and generic versions of established drugs. Notable products in this category include Livaracine, used to treat blood clots and deep vein thrombosis; Yallaferon for viral infections; Slounase, an agent for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection, also for deep vein thrombosis; and Sodium Phenylbutyrate Granules, which treat urea cycle disorders. Conversely, the Licensed-In Products segment manages the distribution and commercialization of pharmaceutical products obtained through licensing agreements with other companies. This extensive portfolio encompasses treatments such as Carnitene for carnitine deficiency; Aloxi and Sancuso for managing chemotherapy-induced nausea and vomiting; Bredinin, an immunosuppressant used in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil, which alleviates oral mucositis pain; Ferplex for iron deficiency anemia; and Gaslon N for gastric ulcers and gastritis. Additional offerings include Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution for primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan, indicated for Stage III and IV Hodgkin's disease; Omacor, containing Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik for Amyotrophic lateral sclerosis; Trittico for insomnia and depression; Unidrox for urinary and respiratory tract infections; the probiotics Dicoflor and VSL#3; and Zingo, a topical local analgesic. Lee's Pharmaceutical was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
What is Lees Pharmaceutical Hldgs stock price today?▼
The current price of LPCUF is $0.19 USD — it has increased by +1.12% in the past 24 hours. Watch Lees Pharmaceutical Hldgs stock price performance more closely on the chart.
What is Lees Pharmaceutical Hldgs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lees Pharmaceutical Hldgs stocks are traded under the ticker LPCUF.
What is Lees Pharmaceutical Hldgs market cap?▼
Today Lees Pharmaceutical Hldgs has the market capitalization of 112.06M
When is the next Lees Pharmaceutical Hldgs earnings date?▼
Lees Pharmaceutical Hldgs is going to release the next earnings report on September 02, 2026.
What is Lees Pharmaceutical Hldgs revenue for the last year?▼
Lees Pharmaceutical Hldgs revenue for the last year amounts to 360.03M USD.
What is Lees Pharmaceutical Hldgs net income for the last year?▼
LPCUF net income for the last year is 23.93M USD.
Does Lees Pharmaceutical Hldgs pay dividends?▼
Yes, LPCUF dividends are paid semi-annual. The last dividend per share was 0 USD. As of today, Dividend Yield (FWD)% is 3.06%.
How many employees does Lees Pharmaceutical Hldgs have?▼
As of June 23, 2026, the company has 1,022 employees.
In which sector is Lees Pharmaceutical Hldgs located?▼
Lees Pharmaceutical Hldgs operates in the Health & Wellness sector.
When did Lees Pharmaceutical Hldgs complete a stock split?▼
Lees Pharmaceutical Hldgs has not had any recent stock splits.
Where is Lees Pharmaceutical Hldgs headquartered?▼
Lees Pharmaceutical Hldgs is headquartered in Sha Tin, Cayman Islands.